Long-term harms from previous use of selective serotonin reuptake inhibitors: A systematic review
Open accessThe DOI matches its Crossref record; 56 of the 57 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Millions of people are treated with antidepressants like selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs). This clinical practice is based on short-term trials that have exaggerated the benefits and underestimated the harms. We also know too little about long-term harms. AIM: To assess harms of SSRIs and SNRIs that persist after end of drug intake. METHODS: Systematic review of placebo-controlled randomised trials of any length in patients with a psychiatric diagnosis and a follow-up of at least six months. Our primary outcomes were mortality, functional outcomes, quality of life and core psychiatric events. We searched PubMed, Embase, and the Cochrane Central Register of Controlled Trials and checked the references for eligible articles. One researcher extracted data and another checked the data extraction. RESULTS: Our searches returned 9,153 unique records. We included 22 papers for 12 trials on SSRIs. Median intervention and follow-up periods were 15 and 52 weeks, respectively. Median number of randomised participants was 51; only two trials had a drop-out rate below 20%. Outcome reporting was less thorough during follow-up than for the intervention period and only two trials maintained the blind during follow-up. All authors concluded that the drugs were not beneficial in the long term. All trials reported harms outcomes selectively or did not report any. Only two trials reported on any of our primary outcomes (school attendance and number of heavy drinking days). CONCLUSION: The randomised trials currently available cannot be used to investigate persistent harms of antidepressants.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Moreover, the symptoms are physical as well as emotional and for some they persist for months or years,21–23 sometimes even after a very slow and careful taper.13,19”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hao (2015) · doi:10.1002/14651858 · Cited by 11,321
Exercise and Pharmacotherapy in the Treatment of Major Depressive Disorder
Blumenthal, J. A., Babyak, M. A., Doraiswamy, P. M., Watkins, L., Hoffman, B. M., Barbour, K. A., Herman, S., Craighead, W. E., Brosse, A. L., Waugh, R., et al. (2007) · Psychosomatic Medicine · doi:10.1097/psy.0b013e318148c19a · Cited by 1,019
Ho, B.-C., Andreasen, N. C., Ziebell, S., Pierson, R., & Magnotta, V. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.199 · Cited by 971 · cited 1×
“Long-term use of psychiatric drugs may cause permanent brain damage, which has been most clearly documented for antipsychotics [20, 21].”
BackgroundDorph-Petersen, K.-A., Pierri, J. N., Perel, J. M., Sun, Z., Sampson, A. R., & Lewis, D. A. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300710 · Cited by 437 · cited 1×
“Long-term use of psychiatric drugs may cause permanent brain damage, which has been most clearly documented for antipsychotics [20, 21].”
BackgroundFava, G. A., Gatti, A., Belaise, C., Guidi, J., & Offidani, E. (2015) · Psychotherapy and Psychosomatics · doi:10.1159/000370338 · Cited by 436 · cited 4×
“It is well known that harms caused by SSRIs can be long-lasting [18] and there are indications that they can even be permanent, e.”
BackgroundInfluentialZimmerman, M., Mattia, J. I., & Posternak, M. A. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.3.469 · Cited by 382 · cited 1×
“in a study that showed that only 41 of 346 (12%) outpatients would qualify for a clinical trial based on common inclusion and exclusion criteria for antidepressant efficacy trials [49].”
BackgroundJakobsen, J. C., Katakam, K. K., Schou, A., Hellmuth, S. G., Stallknecht, S. E., Leth-Møller, K., Iversen, M., Banke, M. B., Petersen, I. J., Klingenberg, S. L., et al. (2017) · BMC Psychiatry · doi:10.1186/s12888-016-1173-2 · Cited by 366 · cited 1×
“Inadequate reporting of harms, even serious harms like deaths, is a general problem for psychiatric drug trials [6, 8, 45, 46], and the discrepancy between data in clinical study reports and in journal publications is disturbing [7, 12, 47, 48].”
BackgroundSharma, T., Guski, L. S., Freund, N., & Gøtzsche, P. C. (2016) · BMJ · doi:10.1136/bmj.i65 · Cited by 319 · cited 3×
“The trials are of short duration, a median of only 9 weeks [8]; withdrawal effects are almost always introduced in the placebo group because the patients were already in treatment before they were randomised; lack of effective blinding; attrition; and selective reporting of major harms [6–8].”
BackgroundSelf-citationAntidepressant discontinuation reactions: Are preventable and simple to treat
Haddad, P., Lejoyeux, M., & Young, A. (1998) · BMJ · doi:10.1136/bmj.316.7138.1105 · Cited by 286
Golder, S., Loke, Y. K., Wright, K., & Norman, G. (2016) · PLOS Medicine · doi:10.1371/journal.pmed.1002127 · Cited by 277 · cited 1×
“Inadequate reporting of harms, even serious harms like deaths, is a general problem for psychiatric drug trials [6, 8, 45, 46], and the discrepancy between data in clinical study reports and in journal publications is disturbing [7, 12, 47, 48].”
BackgroundAdolescent depression: A placebo-controlled fluoxetine treatment study and follow-up
Simeon, J. G., Dinicola, V. F., Ferguson, H. B., & Copping, W. (1990) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/0278-5846(90)90050-q · Cited by 264 · cited 2×
“Two trials were carried out in adolescents [28, 29], while the remaining trials were in adults.”
BackgroundTrends in prescriptions and costs of drugs for mental disorders in England, 1998–2010
Ilyas, S., & Moncrieff, J. (2012) · British Journal of Psychiatry · doi:10.1192/bjp.bp.111.104257 · Cited by 260
Oberlander, T. F., Gingrich, J. A., & Ansorge, M. S. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.201 · Cited by 236 · cited 1×
“Animal studies have shown that prenatal exposure to psychiatric drugs can lead to altered physiology and behaviour later in life [22, 23].”
BackgroundAge Effects on Antidepressant-Induced Manic Conversion
Martin, A., Young, C., Leckman, J. F., Mukonoweshuro, C., Rosenheck, R., & Leslie, D. (2004) · Archives of Pediatrics & Adolescent Medicine · doi:10.1001/archpedi.158.8.773 · Cited by 210 · cited 1×
“Antidepressants have stimulant effects and rather than acknowledging this drug harm, it has led to a diagnosis of bipolar disorder in about 10% of children aged 10–14 years under the care of mental health services [15], which is a far worse disease than depression and is often treated with antipsychotics.”
BackgroundA Controlled Study of Fluvoxamine and Exposure in Obsessive-Compulsive Disorder
COTTRAUX, J., MOLLARD, E., BOUVARD, M., MARKS, I., SLUYS, M., NURY, A. M., DOUGE, R., & CIALDELLA, P. (1990) · International Clinical Psychopharmacology · doi:10.1097/00004850-199001000-00002 · Cited by 203
Hoffman, B. M., Babyak, M. A., Craighead, W. E., Sherwood, A., Murali Doraiswamy, P., Coons, M. J., & Blumenthal, J. A. (2011) · Psychosomatic Medicine · doi:10.1097/psy.0b013e31820433a5 · Cited by 176
Read, J., Cartwright, C., & Gibson, K. (2014) · Psychiatry Research · doi:10.1016/j.psychres.2014.01.042 · Cited by 150
(1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.5.683 · Cited by 144
Persistent Sexual Dysfunction after Discontinuation of Selective Serotonin Reuptake Inhibitors
Csoka, A., Bahrick, A., & Mehtonen, O.-P. (2008) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2007.00630.x · Cited by 131 · cited 1×
“Despite these difficulties, we do know that short term use of antidepressants can cause irritability, anxiety and panic, emotional flattening, dyskinesias [9], sexual impairment [10, 11] and also suicidality and aggression [8], even in healthy adult volunteers [12].”
BackgroundDeadly Medicines and Organised Crime: How Big Pharma Has Corrupted Healthcare
Gøtzsche, P. C. (2013) · Cited by 131
Self-citationRufer, M., Hand, I., Alsleben, H., Braatz, A., Ortmann, J., Katenkamp, B., Fricke, S., & Peter, H. (2004) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-004-0544-8 · Cited by 125 · cited 3×
“Two trials did not exclude patients based on their previous responses to antidepressant drugs [28, 33]; two trials did not report on this [27, 36], while the remaining trials excluded patients based on their history or response to drugs, placebo or therapy.”
BackgroundResultWhitaker, R. (2010) · Cited by 104
Nielsen, M., Hansen, E. H., & Gøtzsche, P. C. (2012) · Addiction · doi:10.1111/j.1360-0443.2011.03686.x · Cited by 103 · cited 1×
“A major reason for this is that they have difficulty coming off the drugs again because of withdrawal effects [17, 18], which for SSRIs are very similar to those the patients experience when they try to stop benzodiazepines [19].”
BackgroundSelf-citationRoest, A. M., de Jonge, P., Williams, C. D., de Vries, Y. A., Schoevers, R. A., & Turner, E. H. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2015.15 · Cited by 101 · cited 1×
“Inadequate reporting of harms, even serious harms like deaths, is a general problem for psychiatric drug trials [6, 8, 45, 46], and the discrepancy between data in clinical study reports and in journal publications is disturbing [7, 12, 47, 48].”
BackgroundPatel, R., Reiss, P., Shetty, H., Broadbent, M., Stewart, R., McGuire, P., & Taylor, M. (2015) · BMJ Open · doi:10.1136/bmjopen-2015-008341 · Cited by 101 · cited 1×
“Similar results have been reported for adults [16].”
ResultCottraux, J. A., Mollard, E., Bouvard, M. A., & Marks, I. M. (1993) · Psychiatry Research · doi:10.1016/0165-1781(93)90030-k · Cited by 96
Hien, D. A., Levin, F. R., Ruglass, L. M., López-Castro, T., Papini, S., Hu, M.-C., Cohen, L. R., & Herron, A. (2015) · Journal of Consulting and Clinical Psychology · doi:10.1037/a0038719 · Cited by 93 · cited 10×
“Three publicly funded trials disclosed conflicts of interest of the authors [30, 35, 38] who were either employed in a drug company or functioned in advisory boards or as consultants for drug companies.”
BackgroundMethodInfluentialZitman, F. G., & Couvée, J. E. (2001) · British Journal of Psychiatry · doi:10.1192/bjp.178.4.317 · Cited by 90 · cited 4×
“The median intervention period was 15 weeks (range 7 to 32 weeks), and the median follow-up after the randomised phase was 52 weeks (range 24 to 364 weeks) for 11 trials; the remaining trial [38] accepted varying follow-up periods ranging from four to 211 weeks).”
BackgroundInfluentialMaund, E., Tendal, B., Hrobjartsson, A., Jorgensen, K. J., Lundh, A., Schroll, J., & Gotzsche, P. C. (2014) · BMJ · doi:10.1136/bmj.g3510 · Cited by 88 · cited 1×
“Inadequate reporting of harms, even serious harms like deaths, is a general problem for psychiatric drug trials [6, 8, 45, 46], and the discrepancy between data in clinical study reports and in journal publications is disturbing [7, 12, 47, 48].”
BackgroundSelf-citationJarrett, R. B., Minhajuddin, A., Gershenfeld, H., Friedman, E. S., & Thase, M. E. (2013) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.1969 · Cited by 87
Sexual Dysfunction Related to Psychotropic Drugs: A Critical Review - Part I: Antidepressants
La Torre, A., Giupponi, G., Duffy, D., & Conca, A. (2013) · Pharmacopsychiatry · doi:10.1055/s-0033-1345205 · Cited by 82
Tardive dysphoria: The role of long term antidepressant use in-inducing chronic depression
El‐Mallakh, R. S., Gao, Y., & Roberts, R. J. (2011) · Medical Hypotheses · doi:10.1016/j.mehy.2011.01.020 · Cited by 81 · cited 1×
“In observational studies, antidepressants have been linked to increased risk of dementia [13]; they may induce depressogenic effects; and the prevalence of treatment-resistant depression appears to be increasing [14].”
Healy, D., Le Noury, J., & Mangin, D. (2018) · International Journal of Risk & Safety in Medicine · doi:10.3233/jrs-180744 · Cited by 81
Fava, G. A., Bernardi, M., Tomba, E., & Rafanelli, C. (2007) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145706007462 · Cited by 80 · cited 1×
“A major reason for this is that they have difficulty coming off the drugs again because of withdrawal effects [17, 18], which for SSRIs are very similar to those the patients experience when they try to stop benzodiazepines [19].”
BackgroundMaund, E., Guski, L. S., & Gøtzsche, P. C. (2017) · Canadian Medical Association Journal · doi:10.1503/cmaj.151104 · Cited by 74
Self-citation12-month follow-up of fluoxetine and cognitive behavioral therapy for binge eating disorder.
Grilo, C. M., Crosby, R. D., Wilson, G. T., & Masheb, R. M. (2012) · Journal of Consulting and Clinical Psychology · doi:10.1037/a0030061 · Cited by 72 · cited 3×
“For the secondary outcomes, three trials reported on remitters [27, 30, 34], and one trial reported on the self-rated Visual Analogue Scale for Depression [37].”
BackgroundResultKim, J.-M., Bae, K.-Y., Stewart, R., Jung, B.-O., Kang, H.-J., Kim, S.-W., Shin, I.-S., Hong, Y. J., Kim, J. H., Shin, H.-Y., et al. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14m09281 · Cited by 71 · cited 5×
“One trial declared no conflicts of interest but was both publicly and privately funded [36]; the remaining trials shared no information on conflicts of interest.”
BackgroundResultInfluentialKreider, A. R., Matone, M., Bellonci, C., dosReis, S., Feudtner, C., Huang, Y.-S. V., Localio, R., & Rubin, D. M. (2014) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2014.05.010 · Cited by 69
Deadly Psychiatry and Organised Denial
Gøtzsche, P. C. (2015) · Research at the University of Copenhagen (University of Copenhagen) · Cited by 68
Self-citationAntidepressant Treatment and Risk of Dementia: A Population-Based, Retrospective Case-Control Study
Lee, C. W.-S., Lin, C.-L., Sung, F.-C., Liang, J.-A., & Kao, C.-H. (2016) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14m09580 · Cited by 61
Bielefeldt, A. Ø., Danborg, P. B., & Gøtzsche, P. C. (2016) · Journal of the Royal Society of Medicine · doi:10.1177/0141076816666805 · Cited by 54 · cited 2×
“Despite these difficulties, we do know that short term use of antidepressants can cause irritability, anxiety and panic, emotional flattening, dyskinesias [9], sexual impairment [10, 11] and also suicidality and aggression [8], even in healthy adult volunteers [12].”
BackgroundSelf-citationThe Psychoactive Effects of Antidepressants and their Association with Suicidality
Goldsmith, L., & Moncrieff, J. (2011) · Current Drug Safety · doi:10.2174/157488611795684622 · Cited by 52 · cited 1×
“Despite these difficulties, we do know that short term use of antidepressants can cause irritability, anxiety and panic, emotional flattening, dyskinesias [9], sexual impairment [10, 11] and also suicidality and aggression [8], even in healthy adult volunteers [12].”
BackgroundMelvin, G. A., Dudley, A. L., Gordon, M. S., Klimkeit, E., Gullone, E., Taffe, J., & Tonge, B. J. (2017) · Child Psychiatry & Human Development · doi:10.1007/s10578-016-0675-y · Cited by 52 · cited 10×
“One study reported that fluoxetine had a positive influence on school attendance, as ten participants (50%) in the fluoxetine group had more than 80% school attendance at end of follow-up compared to four participants (25%) in the placebo group [28], but several other outcomes assessed did not show statistically signi…”
BackgroundMethodResultInfluentialJarrett, R. B., & Thase, M. E. (2010) · Contemporary Clinical Trials · doi:10.1016/j.cct.2010.04.004 · Cited by 51
Chronic exposure to methylphenidate impairs appendicular bone quality in young rats
Komatsu, D. E., Thanos, P. K., Mary, M. N., Janda, H. A., John, C. M., Robison, L. S., Ananth, M. R., Swanson, J. M., Volkow, N. D., & Hadjiargyrou, M. (2012) · Bone · doi:10.1016/j.bone.2012.03.011 · Cited by 50 · cited 1×
“Animal studies have shown that prenatal exposure to psychiatric drugs can lead to altered physiology and behaviour later in life [22, 23].”
BackgroundKim, J., Bae, K., Kang, H., Kim, S., Shin, I., Hong, Y., Kim, J. H., Shin, H., Ahn, Y., Kim, J.-K., et al. (2014) · Psychiatry Investigation · doi:10.4306/pi.2014.11.1.89 · Cited by 49
Escitalopram in the prevention of posttraumatic stress disorder: a pilot randomized controlled trial
Suliman, S., Seedat, S., Pingo, J., Sutherland, T., Zohar, J., & Stein, D. J. (2015) · BMC Psychiatry · doi:10.1186/s12888-015-0391-3 · Cited by 38 · cited 7×
“Only two trials had a drop-out rate below 20% [33, 37].”
BackgroundResultInfluentialde Beurs, E., van Balkom, A. J. L. M., Dyck, R. V., & Lange, A. (1999) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1999.tb05385.x · Cited by 35 · cited 5×
“The tapering method was specifically described for three trials; in one, the medication was stopped abruptly [30], and two described a four-week [31] and a six-week taper [32], respectively.”
BackgroundMethodInfluentialPoorer Long-Term Outcomes among Persons with Major Depressive Disorder Treated with Medication
Vittengl, J. R. (2017) · Psychotherapy and Psychosomatics · doi:10.1159/000479162 · Cited by 26 · cited 1×
“A US national sample (n = 15,365) with a 9-year follow-up found that patients medicated for symptoms of major depressive disorder (measured on several parameters like the Instrumental Activities of Daily Living and the Composite International Interview short-form) had poorer long-term outcomes, based on symptom severi…”
BackgroundCombs, K., Smith, P. J., Sherwood, A., Hoffman, B., Carney, R. M., Freedland, K., Craighead, W. E., & Blumenthal, J. A. (2014) · Journal of Nervous & Mental Disease · doi:10.1097/nmd.0000000000000085 · Cited by 22 · cited 5×
“Three trials had used a scale for a systematic collection of adverse events: the 36-item somatic symptom check list [34], the Fawcett scale [32], and the 58-item side effects for children and adolescents scale [28].”
BackgroundMethodResultInfluentialVittengl, J. R., Clark, L. A., Thase, M. E., & Jarrett, R. B. (2015) · Psychotherapy · doi:10.1037/pst0000021 · Cited by 22
Kim, S. Y., Stewart, R. J., Bae, K., Kim, S., Shin, I., Hong, Y. J., Ahn, Y., Jeong, M. H., Yoon, J., & Kim, J. (2016) · Journal of Affective Disorders · doi:10.1016/j.jad.2016.05.071 · Cited by 21
Vittengl, J. R., Clark, L. A., Thase, M. E., & Jarrett, R. B. (2014) · Journal of Consulting and Clinical Psychology · doi:10.1037/a0037401 · Cited by 20
Kim, J., Stewart, R. J., Bae, K., Kang, H., Kim, S., Shin, I., Hong, Y. J., Ahn, Y., Jeong, M. H., & Yoon, J. (2015) · SLEEP · doi:10.5665/sleep.4822 · Cited by 18
Impaired reproduction after exposure to ADHD drugs: Systematic review of animal studies
Danborg, P. B., Simonsen, A. L., & Gøtzsche, P. C. (2017) · International Journal of Risk & Safety in Medicine · doi:10.3233/jrs-170743 · Cited by 9
Self-citationHughes, S., Cohen, D., & Johnson, R. (2016) · International Journal of Risk & Safety in Medicine · doi:10.3233/jrs-160723 · Cited by 6 · cited 1×
“Inadequate reporting of harms, even serious harms like deaths, is a general problem for psychiatric drug trials [6, 8, 45, 46], and the discrepancy between data in clinical study reports and in journal publications is disturbing [7, 12, 47, 48].”
Background
Research works printed but not linked: 4
- Boesen K, Danborg PB, Gøtzsche PC, Jørgensen KJ. Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults (Protocol). Cochrane Database of Systematic Reviews. 2017, Issue 11 Art. No.: CD012857. PMC8869321 35201607
- Danborg PB, Simonsen AL, Hróbjartsson A, Gøtzsche PC. Long-term changes in observed behavior after exposure to psychiatric drugs: A systematic review of animal studies. Published online, http://nordic.cochrane.org/sites/nordic.cochrane.org/files/public/uploads/danborg_2017_long-term_harms_animal_study.pdf
- Sharma T. Effects of selective serotonin reuptake inhibitors (SSRIs) and serotonin - norepinephrine reuptake inhibitors (SNRIs) on suicidality, violence, and quality of life (PhD Thesis): University of Copenhagen; 2018.
- Tonge BJ, Melvin GA, Dudley AL, Gordon MS. Cognitive behavioural therapy with or without fluoxetine for school refusal: A Randomised controlled trial. RANZCP. 2013; 47: 59, abstract for Royal Australian and New Zealand College of Psychiatrists, RANZCP Annual Congress 2013 Sydney Australia.
Cited by
Canadian Guideline for the Clinical Management of High-Risk Drinking and Alcohol Use Disorder
Wood, E., Bright, J., Hsu, K., Goel, N., Ross, J. W. G., Hanson, A., Teed, R., Poulin, G., Denning, B., Corace, K., et al. (2023) · Canadian Medical Association Journal · doi:10.1503/cmaj.230715 · Cited by 74
“61 Although there is a relatively high degree of consistent findings across naltrexone and acamprosate trials, 18 studies of SSRIs are highly heterogenous, potentially as a result of underlying biases described elsewhere.”
BackgroundWhite, E., Read, J., & Julo, S. (2021) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320981174 · Cited by 63
da Silva, F. J. B., Santos, M. C., & Tesser, C. D. (2022) · Interface - Comunicação Saúde Educação · doi:10.1590/interface.210558 · Cited by 13
What do Climate Change, Nutrition, and the Environment Have to do With Mental Health?
Sugden, S. G., & Merlo, G. (2024) · American Journal of Lifestyle Medicine · doi:10.1177/15598276241280245 · Cited by 10
“5 There are limited long-term randomized clinical controlled trials that con fi rm their ef fi cacy 6 despite the chronicity of depression.”
What have antidepressants been tested for? A systematic review
Gøtzsche, P. C., & Dinnage, O. (2020) · International Journal of Risk & Safety in Medicine · doi:10.3233/jrs-200006 · Cited by 8
“When our research group screened a large amount of papers for a review on long-term harms of antidepressants [3], we noticed that they had been tested for a surprisingly wide range of everyday problems.”
Self-citation
Metadata
- Authors
- Danborg, P. B., Valdersdorf, M., & Gøtzsche, P. C.
- Affiliations
- Rigshospitalet (DK)
- Corresponding author
- Gøtzsche, P.C.
- ORCID
- Gøtzsche, P.C.
- Venue
- International Journal of Risk & Safety in Medicine
- Publisher
- SAGE Publications
- Published
- 2019-05
- Volume
- 30
- Issue
- 2
- Pages
- 59-71
- ISSN
- 0924-6479 (ISSN-L)
- 1878-6847
- PMC
- PMC6839490
- OpenAlex
- W2911290550
- Cited by
- 14
- References
- 57
- Citations by year
- 2026: 3 · 2024: 3 · 2023: 3 · 2022: 1 · 2021: 2 · 2020: 2
- FWCI
- 0.16
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- International Journal of Risk & Safety in Medicine (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by-nc)
- University of Southern Denmark Research Portal (University of Southern Denmark) (publishedVersion, cc-by-nc)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Keywords
- selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, antidepressants, mortality, functional outcome, quality of life, school attendance, heavy drinking, outcome reporting, trial design limitations
- MeSH terms
- Serotonin and Noradrenaline Reuptake Inhibitors, Long Term Adverse Effects, Depression, Humans, Selective Serotonin Reuptake Inhibitors, Risk Assessment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.